IRIDEX CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.85 USD | -0.35% |
|
-5.94% | +1.42% |
| Mar. 26 | Transcript : IRIDEX Corporation, Q4 2023 Earnings Call, Mar 26, 2024 | |
| Mar. 26 | Earnings Flash (IRIX) IRIDEX CORPORATION Reports Q4 Revenue $12.5M, vs. Street Est of $14.9M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +1.42% | 46.32M | - | ||
| +7.15% | 217B | B | ||
| +6.60% | 183B | B- | ||
| +9.86% | 131B | B- | ||
| +24.32% | 106B | A- | ||
| -0.95% | 62.16B | A- | ||
| +11.04% | 51.02B | B+ | ||
| +4.81% | 50.89B | B+ | ||
| -1.43% | 40.16B | A | ||
| +24.40% | 31.44B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IRIX Stock
- Ratings IRIDEX Corporation
